The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

NEW YORK – The first patient with an advanced, MTAP-deleted solid tumor has received Tango Therapeutics' PRMT5 inhibitor TNG456 in a Phase I/II trial, the company said Wednesday. The Boston-based firm ...

NEW YORK – Fractyl Health has submitted the first module of a clinical trial application with European regulators seeking to begin a first-in-human study of its investigational gene therapy for type 2 ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...